v3.25.4
SCHEDULE II. CONDENSED FINANCIAL INFORMATION OF REGISTRANT- Statements of Cash Flows (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]      
Net income (loss) attributable to RenaissanceRe $ 2,682,334 $ 1,870,360 $ 2,561,132
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities      
Net realized and unrealized (gains) losses on investments (1,181,974) (29,439) (482,794)
Other (51,730) (371,707) (579,280)
Net cash provided by (used in) operating activities 3,693,107 4,164,822 1,911,634
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]      
Proceeds from sales and maturities of fixed maturity investments trading 12,687,277 23,515,450 21,796,577
Purchases of fixed maturity investments trading (13,304,154) (26,296,842) (24,771,411)
Return of investments in other ventures 321 41,349 5,554
Net purchase of Validus 0 0 (2,433,746)
Net cash provided by (used in) investing activities (2,215,809) (3,060,856) (3,822,636)
Cash flows provided by (used in) financing activities      
Dividends paid – RenaissanceRe common shares (74,843) (80,849) (75,112)
Dividends paid – preference shares (35,375) (35,375) (35,375)
RenaissanceRe common share repurchases (1,599,680) (666,921) 0
RenaissanceRe common share issuance, net of expenses 0 0 1,351,608
Issuance of debt, net of expenses 889,114 0 740,581
Drawdown of Medici Revolving Credit Facility 75,000 75,000 75,000
Taxes paid on withholding shares (23,522) (23,580) (20,518)
Net cash provided by (used in) financing activities (1,410,503) (1,287,515) 2,588,639
Effect of exchange rate changes on foreign currency cash (12,218) (17,365) 5,542
Net increase (decrease) in cash and cash equivalents 54,577 (200,914) 683,179
Cash and cash equivalents, beginning of year 1,676,604 1,877,518 1,194,339
Cash and cash equivalents, end of year 1,731,181 1,676,604 1,877,518
Parent Company      
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]      
Net income (loss) attributable to RenaissanceRe 2,682,334 1,870,360 2,561,131
Less: equity in net income (loss) of subsidiaries (2,789,729) (2,017,805) (2,708,061)
Loss before equity in net income of subsidiaries (107,395) (147,445) (146,930)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities      
Net realized and unrealized (gains) losses on investments 329 334 67,868
Other 42,289 142,051 72,691
Net cash provided by (used in) operating activities (64,777) (5,060) (6,371)
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]      
Proceeds from sales and maturities of fixed maturity investments trading 528,759 309,490 1,613,740
Purchases of fixed maturity investments trading (423,624) (387,276) (1,505,160)
Net sales (purchases) of short term investments 28,878 147,296 (211,370)
Return of investments in other ventures 1,648,784 1,079,438 1,097,301
Contributions to subsidiaries (356,936) (247,147) (169,204)
Due to (from) subsidiary (45,504) (115,041) (7,088)
Net cash provided by (used in) investing activities 1,380,357 786,760 (1,916,781)
Cash flows provided by (used in) financing activities      
Dividends paid – RenaissanceRe common shares (74,843) (80,850) (75,112)
Dividends paid – preference shares (35,375) (35,375) (35,375)
RenaissanceRe common share repurchases (1,599,680) (666,921) 0
RenaissanceRe common share issuance, net of expenses 0 0 1,351,608
Issuance of debt, net of expenses 493,201 0 740,581
Drawdown of Medici Revolving Credit Facility (55,125) 0 0
Taxes paid on withholding shares (23,522) (23,580) (20,518)
Net cash provided by (used in) financing activities (1,295,344) (806,726) 1,961,184
Effect of exchange rate changes on foreign currency cash 0 0 0
Net increase (decrease) in cash and cash equivalents 20,236 (25,026) 38,032
Cash and cash equivalents, beginning of year 20,054 45,080 7,048
Cash and cash equivalents, end of year 40,290 20,054 45,080
Parent Company | Validus Specialty      
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]      
Due to (from) subsidiary 0 0 (45,467)
Parent Company | Validus Holdings, Ltd and Talbot Underwriting Limited      
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]      
Net purchase of Validus $ 0 $ 0 $ (2,689,533)